| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5697663 | Cancer Treatment Reviews | 2017 | 6 Pages |
Abstract
Most published early phase clinical trials either did not clearly document or did not allow for accrual of patients with CNS disease. Early phase trials with targeted agents or enrolling HER2+ MBC had higher odds of permitting CNS metastases.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
R. Costa, N. Gill, A.W. Rademaker, B.A. Carneiro, Y.K. Chae, P. Kumthekar, W.J. Gradishar, R. Kurzrock, F.J. Giles,